Venture capitalists backed 735 agtech deals across all of 2025. Extrapolate the current trajectory through the first half of 2026 and that number collapses to roughly 525, a decline that has nothing to do with the quality of founders or the urgency of the problems being solved. What changed is not the problem. It is who gets funded to solve it.
The surviving capital is concentrating with sharp purpose. Of the largest ten agtech funding rounds in the first half of 2026, three went to precision agriculture companies, three to animal and aquaculture, two to crop inputs, and one each to vertical farming and farm automation. The median round size is late-stage: Tomorrow.io landed $210 million in Series F; Oishii secured $150 million in Series C; Asto CT raised $83.2 million. These are not seed checks. Meanwhile, analysts tracking the sector describe an explicit investor thesis shift, one captured in a single phrase from the AgTechNavigator H1 2026 VC wrap: investors are moving toward 'agentic ag.' That means systems that 'sense, decide, and act in the field rather than just handing a farmer another recommendation to execute.' The capital is following measurable ROI, water saved, labor hours reduced, inputs cut, not another dashboard.
This reorientation matters more than the headline decline because it names the winner of the next cycle before the cycle begins. Most agtech companies today still automate one crop or one task rather than the whole farm; they still hand the farmer a recommendation and ask him to execute it. The next wave of capital will not fund that model. It will fund systems that eliminate the recommendation step entirely, closed-loop autonomous systems that sense field conditions, decide what action to take, and execute it without farmer intervention. The capital concentration is not random. It is a vote against the entire previous generation of decision-support software.
The exit market amplifies the signal. Venture exits in H1 2026 totaled 30 deals worth $623.2 million, a muted market that forced LPs to sit tight and capital providers to tighten allocation. The one notable exit was Cannatrek, an indoor farming company acquired by Little Green Pharma in a scheme of arrangement announced January 14, 2026, valued in Australian dollars with net assets in excess of approximately $136.7 million. That acquisition was a defensive move in a contracting market, not a validation signal. Analysts quoted in the same AgTechNavigator analysis are explicit about the timeline: '2026 is the bottom of the cycle rather than the year of recovery.' The back half should 'stabilize' deal activity, but no rebound is expected until 2027, when the exit market reopens and LP capital loosens. Even an optimistic second-half scenario, a handful of larger, later-stage rounds, will show up in total dollars, not deal count. Deal volume is 'still grinding lower,' with no reliable seasonal lift to offset structural retrenchment.
For early-stage agtech founders, this is a brutal triage year. Seed and Series A companies without measurable on-farm ROI, without hard numbers on water or labor or fertilizer savings, face a funding desert that now extends through all of 2026 and into 2027. The companies that survive are the ones that can prove a closed-loop system works on a real farm. The companies that disappear are the ones that could not close the loop before the capital drought began. The rebound does not arrive until the exit market reopens and LPs redeploy capital; until then, agtech VC is a game of late-stage concentration and early-stage attrition.